Literature DB >> 19635238

Psychotherapy for obsessive-compulsive disorder.

Eric A Storch1, Amy Mariaskin, Tanya K Murphy.   

Abstract

Cognitive-behavioral therapy (CBT) with exposure and response prevention is a first-line intervention for adult and childhood obsessive-compulsive disorder. Methodologically rigorous controlled trials have suggested that benefits from CBT exceed those from placebo and attention-control conditions and have similar or greater efficacy than serotonergic monotherapy. This article reviews the nature of CBT and associated outcome data, highlighting recent empiric findings in the treatment literature.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19635238     DOI： 10.1007/s11920-009-0043-8

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


  44 in total

Review 1.  Efficacy of combined pharmacotherapy and psychotherapy versus monotherapy in the treatment of anxiety disorders.

Authors:  Donald W Black
Journal:  CNS Spectr       Date:  2006-10       Impact factor: 3.790

2.  Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.

Authors:  David L Walker; Kerry J Ressler; Kwok-Tung Lu; Michael Davis
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

3.  Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.

Authors:  Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

4.  Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder.

Authors:  P van Oppen; E de Haan; A J van Balkom; P Spinhoven; K Hoogduin; R van Dyck
Journal:  Behav Res Ther       Date:  1995-05

5.  Early childhood OCD: preliminary findings from a family-based cognitive-behavioral approach.

Authors:  Jennifer B Freeman; Abbe M Garcia; Lisa Coyne; Chelsea Ale; Amy Przeworski; Michael Himle; Scott Compton; Henrietta L Leonard
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-05       Impact factor: 8.829

Review 6.  Predictors of treatment response in pediatric obsessive-compulsive disorder.

Authors:  Golda S Ginsburg; Julie Newman Kingery; Kelly L Drake; Marco A Grados
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-08       Impact factor: 8.829

7.  Influence of co-morbid generalized anxiety disorder, panic disorder and personality disorders on the outcome of cognitive behavioural treatment of obsessive-compulsive disorder.

Authors:  Bjarne Hansen; Patrick A Vogel; Tore C Stiles; K Gunnar Götestam
Journal:  Cogn Behav Ther       Date:  2007

8.  D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.

Authors:  Eric A Storch; Lisa J Merlo; Michael Bengtson; Tanya K Murphy; Mark H Lewis; Mark C Yang; Marni L Jacob; Michael Larson; Adam Hirsh; Melanie Fernandez; Gary R Geffken; Wayne K Goodman
Journal:  Int Clin Psychopharmacol       Date:  2007-07       Impact factor: 1.659

9.  D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

Authors:  Matt G Kushner; Suck Won Kim; Christopher Donahue; Paul Thuras; David Adson; Michael Kotlyar; James McCabe; Jillian Peterson; Edna B Foa
Journal:  Biol Psychiatry       Date:  2007-06-22       Impact factor: 13.382

10.  Family-based cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: comparison of intensive and weekly approaches.

Authors:  Eric A Storch; Gary R Geffken; Lisa J Merlo; Giselle Mann; Danny Duke; Melissa Munson; Jennifer Adkins; Kristen M Grabill; Tanya K Murphy; Wayne K Goodman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2007-04       Impact factor: 8.829
View more
  5 in total

Review 1.  Excluding the typical patient: thirty years of pharmacotherapy efficacy trials for obsessive-compulsive disorder.

Authors:  Brian L Odlaug; Eric Weinhandl; Maria C Mancebo; Erik L Mortensen; Jane L Eisen; Steven A Rasmussen; Liana R N Schreiber; Jon E Grant
Journal:  Ann Clin Psychiatry       Date:  2014-02       Impact factor: 1.567

2.  D-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders.

Authors:  Meera E Modi; Larry J Young
Journal:  Biol Psychiatry       Date:  2011-04-08       Impact factor: 13.382

Review 3.  Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V.

Authors:  James F Leckman; Damiaan Denys; H Blair Simpson; David Mataix-Cols; Eric Hollander; Sanjaya Saxena; Euripedes C Miguel; Scott L Rauch; Wayne K Goodman; Katharine A Phillips; Dan J Stein
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

4.  Innovations in the Delivery of Exposure and Response Prevention for Obsessive-Compulsive Disorder.

Authors:  Sapana R Patel; Jonathan Comer; Helen Blair Simpson
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 5.  D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis.

Authors:  Jing Xia; Yanqiu Du; Jiyang Han; Guo Liu; Xumei Wang
Journal:  Drug Des Devel Ther       Date:  2015-04-21       Impact factor: 4.162
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.